Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Update of the drug resistance mutations in HIV-1: December 2009.

Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD.

Top HIV Med. 2009 Dec;17(5):138-45. Review. No abstract available.

2.

2011 update of the drug resistance mutations in HIV-1.

Johnson VA, Calvez V, Günthard HF, Paredes R, Pillay D, Shafer R, Wensing AM, Richman DD.

Top Antivir Med. 2011 Nov;19(4):156-64. Review.

3.

Assessments of HIV drug resistance mutations in resource-limited settings.

Jordan MR.

Clin Infect Dis. 2011 Apr 15;52(8):1058-60. doi: 10.1093/cid/cir093. No abstract available.

PMID:
21460325
4.

Update of the Drug Resistance Mutations in HIV-1.

Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD.

Top HIV Med. 2008 Dec;16(5):138-45. Review. Erratum in: Top HIV Med. 2009 Feb-Mar;17(1):13.

5.

Update of the drug resistance mutations in HIV-1: Spring 2008.

Johnson VA, Brun-Vezinet F, Clotet B, Günthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD.

Top HIV Med. 2008 Apr-May;16(1):62-8. No abstract available. Erratum in: Top HIV Med. 2008 Oct-Nov;16(4):121.

6.

Update of the drug resistance mutations in HIV-1: 2007.

Johnson VA, Brun-Vézinet F, Clotet B, Günthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD.

Top HIV Med. 2007 Aug-Sep;15(4):119-25. Review. No abstract available.

7.

[Evolution of HIV resistance mutations in the Valme referral center].

Nogales MC, Castro C, Martín-Mazuelos E.

Enferm Infecc Microbiol Clin. 2007 Feb;25(2):159. Spanish. No abstract available.

PMID:
17288915
8.

HIV drug resistance tests: an update on methods for calculating phenotypic fold change from a viral genotype.

Bellosillo NA, Bacheler L, Villacian J.

Clin Infect Dis. 2009 Mar 1;48(5):687; author reply 687. doi: 10.1086/597016. No abstract available.

PMID:
19191661
9.

HIV-1 integrase variability and relationship with drug resistance in antiretroviral-naive and -experienced patients with different HIV-1 subtypes.

Reigadas S, Marcelin AG, Houssaïni A, Yerly S, Descamps D, Plantier JC, Ruffault A, Amiel C, Trabaud MA, Flandre P, Fleury H, Masquelier B; ANRS AC11 Resistance Study Group.

J Antimicrob Chemother. 2013 Apr;68(4):969-72. doi: 10.1093/jac/dks474. Epub 2012 Nov 25. No abstract available.

PMID:
23184711
10.

HIV-1 drug resistance in variants from the female genital tract and plasma.

Kemal KS, Burger H, Mayers D, Anastos K, Foley B, Kitchen C, Huggins P, Schroeder T, Picchio G, Back S, Gao W, Meyer WA 3rd, Weiser B.

J Infect Dis. 2007 Feb 15;195(4):535-45. Epub 2007 Jan 8.

PMID:
17230413
11.

Update of the drug resistance mutations in HIV-1: 2004.

Johnson VA, Brun-Vézinet F, Clotet B, Conway B, D'Aquila RT, Demeter LM, Kuritzkes DR, Pillay D, Schapiro JM, Telenti A, Richman DD.

Top HIV Med. 2004 Oct-Nov;12(4):119-24. Review. No abstract available.

12.

[Prevalence of antiretroviral drug genotypic resistance among HIV patients in Cuenca, Spain].

Rodriguez-Escudero MJ, Prada de Medio E, Rosa Herranz C, Martinez Medina MC, Franquelo Gutierrez R.

Rev Esp Quimioter. 2007 Jun;20(2):203-5. Spanish.

13.

Nine-year trends in clinically relevant reduced susceptibility of HIV-1 to antiretrovirals.

Sista P, Rinehart A, Wasikowski B, Winters B, Pattery T, Bacheler L.

J Clin Virol. 2009 Mar;44(3):190-4. doi: 10.1016/j.jcv.2008.12.005. Epub 2009 Jan 24.

PMID:
19168389
14.

Optimized protocol for detection of HIV-1 drug mutations in patients with low viral load.

Stelzl E, Troppan KT, Winkler M, Korn K, Kessler HH.

J Virol Methods. 2010 Sep;168(1-2):152-4. doi: 10.1016/j.jviromet.2010.05.007. Epub 2010 May 13.

PMID:
20471425
15.

When do minority drug-resistant HIV-1 variants have a major clinical impact?

Heneine W.

J Infect Dis. 2010 Mar;201(5):647-9. doi: 10.1086/650545. No abstract available.

PMID:
20102273
16.

Possibility of HIV-1 resistance mutations in cerebrospinal fluid from persons receiving suppressive therapy.

Seligman SJ.

J Infect Dis. 2011 Jul 1;204(1):174; author reply 174-5. doi: 10.1093/infdis/jir234. No abstract available.

17.

Are the proposed env mutations actually associated with resistance to maraviroc?

Saracino A, Monno L, Brindicci G, Trillo G, Altamura M, Punzi G, Lagioia A, Angarano G.

J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):550-2. doi: 10.1097/QAI.0b013e3181ba46a6. No abstract available.

PMID:
20220379
18.

Detection and significance of minority quasispecies of drug-resistant HIV-1.

Metzner KJ.

J HIV Ther. 2006 Dec;11(4):74-81. Review. No abstract available.

PMID:
17578210
19.

Low-frequency HIV-1 drug resistance mutations can be clinically significant but must be interpreted with caution.

Johnson JA, Geretti AM.

J Antimicrob Chemother. 2010 Jul;65(7):1322-6. doi: 10.1093/jac/dkq139. Epub 2010 May 13. Review.

PMID:
20466851
20.

Trends in antiretroviral drug resistance and clade distributions among HIV-1--infected blood donors in Sao Paulo, Brazil.

Barreto CC, Nishyia A, Araújo LV, Ferreira JE, Busch MP, Sabino EC.

J Acquir Immune Defic Syndr. 2006 Mar;41(3):338-41.

PMID:
16540943

Supplemental Content

Support Center